在模拟口服400毫克单剂量头孢妥仑匹酯后尿液浓度的体外药效学模型中，尿液对表现出不同耐药表型/基因型的大肠杆菌分离株的杀菌活性。
Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil.
作者信息
Sevillano David, Aguilar Lorenzo, Alou Luis, Giménez María-José, Torrico Martha, González Natalia, Cafini Fabio, Relaño María-Teresa, Coronel Pilar, Prieto José
机构信息
Microbiology Department, School of Medicine, Universidad Complutense, Avda. Complutense s/n, 28040 Madrid, Spain.
出版信息
Antimicrob Agents Chemother. 2008 Mar;52(3):1184-6. doi: 10.1128/AAC.01247-07. Epub 2007 Dec 26.
Abstract
Activity of simulated cefditoren urinary concentrations was determined against seven Escherichia coli isolates. Bactericidal activity was obtained from 4 to 24 h against TEM-1 (penicillinase production/hyperproduction), TEM-34 (IRT-6), and TEM-116 (extended-spectrum beta-lactamase [ESBL]) and from 6 to 8 h against SHV/TEM-116 (ESBL) but never against SHV/TEM-1 (ESBL). Extension of bactericidal activity depended on the resistance genotype/phenotype tested.
摘要
测定了模拟头孢妥仑尿液浓度对七株大肠杆菌分离株的活性。在4至24小时内对TEM-1（产青霉素酶/高产青霉素酶）、TEM-34（IRT-6）和TEM-116（超广谱β-内酰胺酶[ESBL]）有杀菌活性，在6至8小时内对SHV/TEM-116（ESBL）有杀菌活性，但对SHV/TEM-1（ESBL）从未有杀菌活性。杀菌活性的延长取决于所测试的耐药基因型/表型。
相似文献
1
Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil.
Antimicrob Agents Chemother. 2008 Mar;52(3):1184-6. doi: 10.1128/AAC.01247-07. Epub 2007 Dec 26.
2
Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases.
Int J Antimicrob Agents. 2005 Jun;25(6):479-87. doi: 10.1016/j.ijantimicag.2005.02.012.
3
Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.
Antimicrob Agents Chemother. 2004 Jun;48(6):1941-7. doi: 10.1128/AAC.48.6.1941-1947.2004.
4
In vitro activity of temocillin against extended spectrum beta-lactamase-producing Escherichia coli.
J Antimicrob Chemother. 2006 Apr;57(4):771-4. doi: 10.1093/jac/dkl046. Epub 2006 Feb 24.
5
CTX-M-producing Escherichia coli and Klebsiella pneumoniae isolated from community-acquired urinary tract infections in Valledupar, Colombia.
Braz J Infect Dis. 2012 Sep-Oct;16(5):420-5. doi: 10.1016/j.bjid.2012.05.001. Epub 2012 Sep 8.
6
Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration.
J Antimicrob Chemother. 2006 Apr;57(4):714-9. doi: 10.1093/jac/dkl041. Epub 2006 Feb 21.
7
Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
J Antimicrob Chemother. 2009 Oct;64(4):824-8. doi: 10.1093/jac/dkp254. Epub 2009 Jul 29.
8
Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway.
J Clin Microbiol. 2007 Jan;45(1):199-205. doi: 10.1128/JCM.01319-06. Epub 2006 Nov 1.
9
beta-lactam susceptibility of Escherichia coli isolates from urinary tract infections exhibiting different resistance phenotypes.
Rev Esp Quimioter. 2008 Sep;21(3):149-52.
10
SHV-5 extended-spectrum beta-lactamases in clinical isolates of Escherichia coli in Malaysia.
Indian J Med Microbiol. 2006 Jul;24(3):205-7.
引用本文的文献
1
[Role of cefditoren in the treatment of community skin and soft tissue infections: revisiting the evidence].
Rev Esp Quimioter. 2021 Jun;34(3):185-192. doi: 10.37201/req/063.2021. Epub 2021 May 24.
2
Cefditoren: Comparative efficacy with other antimicrobials and risk factors for resistance in clinical isolates causing UTIs in outpatients.
BMC Infect Dis. 2012 Sep 25;12:228. doi: 10.1186/1471-2334-12-228.
本文引用的文献
1
influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene.
Antimicrob Agents Chemother. 2007 Oct;51(10):3699-706. doi: 10.1128/AAC.01530-06. Epub 2007 Jul 30.
2
3
Analysis of plasmids encoding extended-spectrum beta-lactamases (ESBLs) from Escherichia coli isolated from non-hospitalised patients in Seville.
Int J Antimicrob Agents. 2007 Jan;29(1):89-92. doi: 10.1016/j.ijantimicag.2006.08.027.
4
Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration.
J Antimicrob Chemother. 2006 Apr;57(4):714-9. doi: 10.1093/jac/dkl041. Epub 2006 Feb 21.
5
Bactericidal activity of oral beta-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum beta-lactamases.
Int J Antimicrob Agents. 2005 Jun;25(6):479-87. doi: 10.1016/j.ijantimicag.2005.02.012.
6
[Etiology and antimicrobial susceptibility among uropathogens causing community-acquired lower urinary tract infections: a nationwide surveillance study].
Enferm Infecc Microbiol Clin. 2005 Jan;23(1):4-9. doi: 10.1157/13070401.
7
Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase-producing Escherichia coli in nonhospitalized patients.
J Clin Microbiol. 2004 Mar;42(3):1089-94. doi: 10.1128/JCM.42.3.1089-1094.2004.
8
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.
Antimicrob Agents Chemother. 2004 Feb;48(2):369-77. doi: 10.1128/AAC.48.2.369-377.2004.
9
[Phenotypes of resistance in community urinary tract isolates of Escherichia coli: therapeutic implications].
Med Clin (Barc). 2003 Mar 22;120(10):361-4. doi: 10.1016/s0025-7753(03)73705-1.
10
Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States.
Antimicrob Agents Chemother. 2002 Aug;46(8):2540-5. doi: 10.1128/AAC.46.8.2540-2545.2002.
Zotero 插件